|
|
Home
Search
Study Topics
Glossary
|
 |
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||||||||||||||
| Tracking Information | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| First Received Date ICMJE | April 24, 2002 | ||||||||
| Last Updated Date | August 24, 2009 | ||||||||
| Start Date ICMJE | April 2002 | ||||||||
| Estimated Primary Completion Date | March 2005 (final data collection date for primary outcome measure) | ||||||||
| Current Primary Outcome Measures ICMJE | |||||||||
| Original Primary Outcome Measures ICMJE | |||||||||
| Change History | Complete list of historical versions of study NCT00034216 on ClinicalTrials.gov Archive Site | ||||||||
| Current Secondary Outcome Measures ICMJE | |||||||||
| Original Secondary Outcome Measures ICMJE | |||||||||
| Descriptive Information | |||||||||
| Brief Title ICMJE | Collection of Blood From Patients With Cancer | ||||||||
| Official Title ICMJE | Collection of Blood From Patients With Cancer | ||||||||
| Brief Summary | This study will collect blood from patients with cancer to study the level of cells which decrease the immune response (suppressor cells) before and after chemotherapy. Patients 18 years of age and older with cancer may participate. This study does not involve treatment. Participants will have about 50 ml (3 tablespoonfuls) of blood drawn. Depending on their condition, patients may be invited to enroll in a clinical research study involving chemotherapy, radiotherapy, or surgery. Additional 40-ml blood samples may be drawn during the course of treatment. |
||||||||
| Detailed Description | Patients with a prior diagnosis of malignancy or refractory cancer will be evaluated in the Medical Oncology Clinic, NCI. Blood samples may be collected at the initial visit and at follow-up visits. Blood samples will be processed and stored in the Laboratory of Tumor Immunology and Biology or Frederick for use in research efforts. |
||||||||
| Study Phase | |||||||||
| Study Type ICMJE | Observational | ||||||||
| Study Design ICMJE | |||||||||
| Condition ICMJE | Neoplasms | ||||||||
| Intervention ICMJE | |||||||||
| Study Arms / Comparison Groups | |||||||||
| Publications * |
|
||||||||
|
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline. |
|||||||||
| Recruitment Information | |||||||||
| Recruitment Status ICMJE | Recruiting | ||||||||
| Enrollment ICMJE | 100 | ||||||||
| Completion Date | |||||||||
| Estimated Primary Completion Date | March 2005 (final data collection date for primary outcome measure) | ||||||||
| Eligibility Criteria ICMJE |
Patients 18 years of age and older are eligible. Patients must have a performance status of ECOG 0, 1, 2, or 3 for admission to this protocol. Patients with malignancy are eligible. EXCLUSION CRITERIA: Children will not be eligible. |
||||||||
| Gender | Both | ||||||||
| Ages | 18 Years and older | ||||||||
| Accepts Healthy Volunteers | No | ||||||||
| Contacts ICMJE |
|
||||||||
| Location Countries ICMJE | United States | ||||||||
| Administrative Information | |||||||||
| NCT ID ICMJE | NCT00034216 | ||||||||
| Responsible Party | |||||||||
| Study ID Numbers ICMJE | 020179, 02-C-0179 | ||||||||
| Study Sponsor ICMJE | National Cancer Institute (NCI) | ||||||||
| Collaborators ICMJE | |||||||||
| Investigators ICMJE | |||||||||
| Information Provided By | National Institutes of Health Clinical Center (CC) | ||||||||
| Verification Date | November 2008 | ||||||||
|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |
|||||||||
